Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RORC | P51449 | 16/20 | 0.46 |
| ▸ | RARG | P13631 | 4/20 | 0.43 |
| ▸ | KCNJ5 | P48544 | 1/20 | 0.39 |
| ▸ | KCNJ3 | P48549 | 1/20 | 0.39 |
| ▸ | GSK3A | P49840 | 1/20 | 0.38 |
| ▸ | GSK3B | P49841 | 1/20 | 0.38 |
| ▸ | PPARG | P37231 | 1/20 | 0.37 |
| ▸ | TTR | P02766 | 1/20 | 0.36 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16611192 | 0.91 | KCNJ5 (0.39) | RORCRARGKCNJ5KCNJ3SCN9A | |
| SCHEMBL16610793 | 0.90 | RORC (0.40) | RORCRARGKCNJ5KCNJ3SCN9A | |
| SCHEMBL16611950 | 0.88 | RORC (0.44) | RORCRARGKCNJ5KCNJ3SCN9A | |
| SCHEMBL16611435 | 0.82 | KCNJ5 (0.42) | KCNJ5KCNJ3 | |
| SCHEMBL16611684 | 0.81 | RORC (0.43) | RORCRARGTTR | |
| SCHEMBL16611463 | 0.81 | KCNJ5 (0.37) | KCNJ5KCNJ3 | |
| SCHEMBL16610791 | 0.80 | KCNJ5 (0.36) | KCNJ5KCNJ3 | |
| SCHEMBL16610870 | 0.78 | KCNJ5 (0.41) | KCNJ5KCNJ3 | |
| SCHEMBL16611410 | 0.78 | KCNJ5 (0.36) | KCNJ5KCNJ3SCN9A | |
| SCHEMBL16610883 | 0.76 | PTGS2 (0.33) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20160251352-A1 | HETEROCYCLIC COMPOUND | TAKEDA PHARMACEUTICALS CO (JP) | 2016-09-01 | — | — | US | disclosed |
| US-9371320-B2 | Heterocyclic compound | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2016-06-21 | — | — | US | disclosed |
| US-20150141406-A1 | HETEROCYCLIC COMPOUND | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2015-05-21 | — | — | US | disclosed |
| EP-2857400-A1 | HETEROCYCLIC COMPOUND | Takeda Pharmaceutical Company Limited (JP) | 2015-04-08 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160251352-A1 | HETEROCYCLIC COMPOUND | JAK2, JAK1, STAT3 | RORC 538/4885RARG 695/4885KCNJ5 2242/4885 |
| US-20150141406-A1 | HETEROCYCLIC COMPOUND | JAK2, JAK1, STAT3 | RORC 538/4885RARG 695/4885KCNJ5 2242/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.